D3813
Anti-DR4, N-Terminal antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Sinónimos:
Anti-Death Receptor 4, Anti-TRAIL-R1
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
En este momento no podemos mostrarle ni los precios ni la disponibilidad
origen biológico
rabbit
Nivel de calidad
conjugado
unconjugated
forma del anticuerpo
IgG fraction of antiserum
tipo de anticuerpo
primary antibodies
clon
polyclonal
Formulario
buffered aqueous solution
mol peso
antigen approximately 57 kDa
reactividad de especies
human
técnicas
microarray: suitable
western blot: 0.5 μg/mL using human HeLa cell extract
Nº de acceso UniProt
Condiciones de envío
dry ice
temp. de almacenamiento
−20°C
Información sobre el gen
human ... TNFRSF10A(8797)
Descripción general
DR4, referred to as TRAIL Receptor-1, is a novel death domain containing receptor whose ligand has been identified as TRAIL or apoptosis-inducing ligand 2 (Apo2L). It is a member of the TNF superfamily of receptors that induce apoptosis. It is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine, and thymus.
Inmunógeno
synthetic peptide corresponding to amino acids 1-20 of the N-terminal of the mature human DR4.
Aplicación
Anti-DR4 antibody produced in rabbit is suitable for microarray and immunoblotting at a working dilution of 1:500-1:1000 using total HeLa, K562, and Jurkat whole cell lysates. It was used as a primary antibody in the immunodetection of DR4 in cell lysate of human small cell lung carcinoma cells. It was used as a primary antibody in the immunoblot analysis of fetal and adenocarcinoma epithelial colon cells in a study.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Acciones bioquímicas o fisiológicas
DR4 induces apoptosis in a variety of human tumor cell lines, but not in normal cells and activates NF-κB.
Forma física
Solution in phosphate buffered saline containing 0.02% sodium azide
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
10 - Combustible liquids
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Lenka Kočí et al.
Cytokine, 55(1), 34-39 (2011-04-13)
The resistance of transformed epithelial cells to a detachment-induced apoptosis (anoikis) can significantly affect their susceptibility to anticancer therapy. We showed that detachment of both fetal (FHC) and adenocarcinoma (HT-29) human colon epithelial cells resulted in the activation of the
P Schneider et al.
Immunity, 7(6), 831-836 (1998-01-16)
TRAIL induces apoptosis through two closely related receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Here we show that TRAIL-R1 can associate with TRAIL-R2, suggesting that TRAIL may signal through heteroreceptor signaling complexes. Both TRAIL receptors bind the adaptor molecules FADD and
Alena Vaculova et al.
Molecular cancer, 9, 87-87 (2010-04-27)
TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a
S R Wiley et al.
Immunity, 3(6), 673-682 (1995-12-01)
A novel tumor necrosis factor (TNF) family member has been cloned and characterized. This protein, designated TNF-related apoptosis-inducing ligand (TRAIL), consists of 281 and 291 aa in the human and murine forms, respectively, which share 65% aa identity. TRAIL is
Sarita Das et al.
Oncotarget, 8(1), 248-267 (2016-08-20)
Death Receptor 5 (DR5) is known to be an important anti-cancer drug target. TRAIL is a natural ligand of DR5, but its drug action is limited because of several factors. A few agonistic ligands were identified as TRAIL-DR5 axis modulators
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
